SQZ Biotechnologies Price to Sales Ratio 2020-2022 | SQZ

Historical PS ratio values for SQZ Biotechnologies (SQZ) over the last 10 years. The current P/S ratio for SQZ Biotechnologies as of June 28, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
SQZ Biotechnologies P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-06-28 3.25 3.69
2022-03-31 4.81 $0.88 5.45
2021-12-31 8.93 $0.99 9.04
2021-09-30 14.42 $1.00 14.42
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.095B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $170.283B 10.36
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.670B 16.84
Biohaven Pharmaceutical Holding (BHVN) United States $10.157B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.957B 0.00
Arcus Biosciences (RCUS) United States $1.815B 46.02
Emergent Biosolutions (EBS) United States $1.640B 7.02
Myovant Sciences (MYOV) United Kingdom $1.243B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.098B 0.00
Ambrx Biopharma (AMAM) United States $0.098B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00